Congress Should Pass Legislation To Ban Agreements To Delay Market Entry Of Generic Medications, Editorial States

... Two "excessively lenient" court decisions have allowed agreements in which brand-name pharmaceutical companies pay generic pharmaceutical companies to delay market entry of their products, a "costly legal loophole that needs to be plugged" by Congress, a New York Times editorial states. [click link for full article] ...